Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7729 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Steminent Biotherapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Steminent Biotherapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Steminent Biotherapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Steminent Biotherapeutics's Days Payable falls into.
Steminent Biotherapeutics Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Steminent Biotherapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Steminent Biotherapeutics (ROCO:7729) has a Days Payable of 0.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Steminent Biotherapeutics and its competitors. Over the past decade, Steminent Biotherapeutics' Days Payable has ranged from 13.71 to 1,254.02. According to the industry distribution chart, Steminent Biotherapeutics ranks #96 out of 701 companies in the Biotechnology industry, placing it in the top 13.7%.
Is Steminent Biotherapeutics' Days Payable too high?
Steminent Biotherapeutics' current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 13.71 to a high of 1,254.02. Based on the distribution chart, Steminent Biotherapeutics ranks #96 out of 701 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Steminent Biotherapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Steminent Biotherapeutics' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Steminent Biotherapeutics ranks #96 out of 701 companies for Days Payable. This places Steminent Biotherapeutics in the top 14% of its industry — outperforming the majority of peers. The industry median Days Payable is 112.84. Historically, Steminent Biotherapeutics' own Days Payable has ranged from 13.71 to 1,254.02 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Steminent Biotherapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Steminent Biotherapeutics's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Steminent Biotherapeutics stock overvalued right now?
Steminent Biotherapeutics (ROCO:7729) has a current Days Payable of 0.00. The current Days Payable is 0.00. Steminent Biotherapeutics' overall GF Score™ is 11/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Steminent Biotherapeutics (ROCO:7729), the current Days Payable is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Steminent Biotherapeutics Inc is a international stem cell biopharmaceutical company which has stable and efficient stem cell platform technology, aiming to develop live cell drugs to treat degenerative diseases as well as acute and life-threatening diseases. With its Stemchymal which is proprietary technology platform generating the standardized, clinical grade, allogeneic stem cells isolated from human adipose tissue. It is operated in strict compliance to regulations of Taiwan, the US, and Japan.
11GF Score
Get the complete analysis for ROCO:7729
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7729 has been successfully added to your 
